Evidence map›Paper›PMID 31496122›Full record

ArticleAging cell2019

Reversal of epigenetic aging and immunosenescent trends in humans.

Gregory M Fahy, Robert T Brooke, James P Watson, Zinaida Good, Shreyas S Vasanawala, Holden Maecker, Michael D Leipold, David T S Lin, Michael S Kobor, Steve Horvath

3 registry-linked trialsAbstract read
In one paragraph

Article in Aging cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 297 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
297citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06975111 phase2 / phase3recruitingstarted 2026, after this paper: background citation

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Ran2026Enrolled200Registered outcomes10Posted comparisons0ConditionsCardiovascular, Menopause, Menopause Hot Flashes, Menopause Related ConditionsArmsAnti-hypertensives, Fezolinetant, Hormonal therapy, Life Style Intervention, Lipid Lowering Medication
Open the trial in the graph
NCT04375657 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial

TypeinterventionalSponsorIntervene Immune, Inc.Ran2020 to 2025Enrolled85ConditionsEpigenetic Aging, ImmunosenescenceArmsTRIIM Treatment, Active Control
NCT05655000 naunknown statusnot on this mapstarted 2022, after this paper: background citation

A First-in-Humans Supermicrosurgical Technique for the Neonatal Thymus Transplantation

TypeinterventionalSponsorFundacion Clinica Valle del LiliRan2022 to 2023Enrolled1ConditionsSafety IssuesArmsNeonatal thymus transplantation
3 · Its place in the literature

Who cites it

297 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. DNA methylation GrimAge acceleration in US military veterans with PTSD.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Article
  17. [Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Article
  18. Extracellular vesicles and epigenetic aging clocks in tissue aging: an exosome-focused conceptual framework with a focus on skin.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Review
  19. Review
  20. Article

237 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Gregory M FahyIntervene Immune, Los Angeles, CA, USA.ORCID 0000-0003-0445-7385
Robert T BrookeIntervene Immune, Los Angeles, CA, USA.ORCID 0000-0001-8492-5198
James P WatsonUCLA Division of Plastic and Reconstructive Surgery, David Geffen School of Medicine, Los Angeles, CA, USA.
Zinaida GoodDepartments of Microbiology and Immunology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-2343-5771
Shreyas S VasanawalaStanford Medical Center, Stanford, CA, USA.ORCID 0000-0002-1999-6595
Holden MaeckerInstitute for Immunity, Transplantation and Infection, Stanford School of Medicine, Human Immune Monitoring Center, Stanford, CA, USA.
Michael D LeipoldInstitute for Immunity, Transplantation and Infection, Stanford School of Medicine, Human Immune Monitoring Center, Stanford, CA, USA.ORCID 0000-0001-5389-0906
David T S LinDepartment of Medical Genetics, BC Children's Hospital Research Institute, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-5695-9446
Michael S KoborDepartment of Medical Genetics, BC Children's Hospital Research Institute, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-4140-1743
Steve HorvathHuman Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0002-4110-3589

Funding

Validation and optimization of epigenetic clocksU01AG060908 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RITZ, BEATE R. · 2018 to 2022
$3.4M
Intervene Immune, IncNIA NIH HHS U01 AG060908
6 · The paper itself

Abstract

Epigenetic "clocks" can now surpass chronological age in accuracy for estimating biological age. Here, we use four such age estimators to show that epigenetic aging can be reversed in humans. Using a protocol intended to regenerate the thymus, we observed protective immunological changes, improved risk indices for many age-related diseases, and a mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment (-2.5-year change compared to no treatment at the end of the study). The rate of epigenetic aging reversal relative to chronological age accelerated from -1.6 year/year from 0-9 month to -6.5 year/year from 9-12 month. The GrimAge predictor of human morbidity and mortality showed a 2-year decrease in epigenetic vs. chronological age that persisted six months after discontinuing treatment. This is to our knowledge the first report of an increase, based on an epigenetic age estimator, in predicted human lifespan by means of a currently accessible aging intervention.

Indexed as

ImmunosenescenceAgedAgingEpigenesis, GeneticHealthy VolunteersHumansLongevityMaleMiddle Agedc-reactive proteinlymphocyte-to-monocyte rationaive T cellsPD-1PSAthymic regeneration

Identifiers

PMID31496122
PMCPMC6826138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.